Literature DB >> 18618617

A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis.

Hajime Yamamoto1, Etsuro Yamaguchi, Hiroatsu Agata, Nobuhisa Kandatsu, Toru Komatsu, Seiko Kawai, Kenji Baba, Tomonari Awaya, Ryuta Nishikomori, Masahito Tsurusawa, Koh Nakata.   

Abstract

Systemic and inhalation therapy of granulocyte-macrophage colony-stimulating factor (GM-CSF) is usually effective in controlling autoimmune pulmonary alveolar proteinosis (PAP), but some cases are refractory to GM-CSF therapy and subjected to whole lung lavage (WLL). A 9-year-old girl developed severe respiratory failure due to autoimmune PAP was treated with inhalational 250 microg of GM-CSF daily, however, it was ineffective. Unilateral WLL was performed three times and subsequent GM-CSF inhalation therapy yielded marked physiological and radiological improvement and was continued for 1 year. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618617     DOI: 10.1002/ppul.20856

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  12 in total

1.  Autoimmune pulmonary proteinosis in a Chilean teenager, a rare aetiology of interstitial lung disease.

Authors:  Alexis Strickler; Maria Lina Boza; Andres Koppmann; Sergio Gonzalez
Journal:  BMJ Case Rep       Date:  2014-05-23

2.  Interstitial Lung Disease in Children Older Than 2 Years.

Authors:  Timothy J Vece; Leland L Fan
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2010-03       Impact factor: 1.349

3.  Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.

Authors:  Ryushi Tazawa; Bruce C Trapnell; Yoshikazu Inoue; Toru Arai; Toshinori Takada; Yasuyuki Nasuhara; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masayuki Hojo; Haruyuki Ishii; Masanori Yokoba; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Yoshiko Tsuchihashi; Konosuke Morimoto; Masanori Akira; Masaki Terada; Junji Otsuka; Masahito Ebina; Chinatsu Kaneko; Toshihiro Nukiwa; Jeffrey P Krischer; Kohei Akazawa; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2010-02-18       Impact factor: 21.405

4.  Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.

Authors:  Spyros A Papiris; Panagiotis Tsirigotis; Likurgos Kolilekas; Georgia Papadaki; Andriana I Papaioannou; Christina Triantafillidou; Anastasia Papaporfyriou; Anna Karakatsani; Konstantinos Kagouridis; Matthias Griese; Effrosyni D Manali
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

5.  Successful Treatment of Autoimmune Pulmonary Alveolar Proteinosis in a Pediatric Patient.

Authors:  Mirjana Trukalj; Marija Perica; Željko Ferenčić; Damir Erceg; Marta Navratil; Gzim Redžepi; Boro Nogalo
Journal:  Am J Case Rep       Date:  2016-09-05

6.  The effectiveness of N-acetylcysteine for an adult case of pulmonary alveolar proteinosis: A case report.

Authors:  Haiyan Zhang
Journal:  Respir Med Case Rep       Date:  2019-06-14

7.  SP-D counteracts GM-CSF-mediated increase of granuloma formation by alveolar macrophages in lysinuric protein intolerance.

Authors:  David N Douda; Nicole Farmakovski; Sharon Dell; Hartmut Grasemann; Nades Palaniyar
Journal:  Orphanet J Rare Dis       Date:  2009-12-23       Impact factor: 4.123

8.  Pulmonary alveolar proteinosis: diagnostic and therapeutic challenges.

Authors:  Ilaria Campo; Zamir Kadija; Francesca Mariani; Elena Paracchini; Giuseppe Rodi; Francesco Mojoli; Antonio Braschi; Maurizio Luisetti
Journal:  Multidiscip Respir Med       Date:  2012-06-11

9.  A pediatric case of relapsed pulmonary alveolar proteinosis despite successful whole lung lavage.

Authors:  Seung Young Jin; Hye Ri Yun; Yun Jung Choi; Jun Dong Park; Jin Tae Kim; Chang Hyun Kang; Young Sik Park; Young Hun Choi; Woo Sun Kim; Dong In Suh
Journal:  Korean J Pediatr       Date:  2017-07-31

10.  Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim).

Authors:  Marta E Gajewska; Sajitha S Sritharan; Eric Santoni-Rugiu; Elisabeth M Bendstrup
Journal:  Respir Med Case Rep       Date:  2018-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.